A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group.

In a retrospective study involving 32 haematology/oncology departments in France, 348 cases of Langerhans' cell histiocytosis diagnosed between 1983 and 1993 were collated. The percentage of males was 56.4%. Median age at diagnosis was 30.2 months. The median follow up was 35.5 months. Initially, 108 patients (31%) had isolated unifocal or bifocal bone involvement, 67 (19%) had isolated multifocal bone involvement, 136 (39%) had soft tissue involvement without organ dysfunction, and 37 (11%) had organ dysfunction. Two thirds of the sites of involvement diagnosed throughout the course of the disease were present at diagnosis, while the remaining one third appeared during a relapse. Treatment was tailored to the individual patient and was extremely varied, hampering any comparison of regimens. Vinblastine with or without steroids was the most common regimen when systemic chemotherapy was used for the first episode (246/348). Twenty four of the 216 patients received VP 16 as first line treatment. Two patients with progressive multiorgan relapse, despite the use of several drugs, underwent bone marrow transplantation and are alive and disease free 60 and 22 months later. Altogether 21.9% of patients had sequelae, including diabetes insipidus in 17.5% of cases. The overall survival rate is 91.7% (confidence interval 90.7 to 95%) three years after diagnosis. In the univariate analysis, age less than 1 year, ear, nose, and throat, cutaneous, lymph node, liver, spleen, lung, marrow and intestinal involvement, male sex, progressive episodes, the absence of response, and partial responses, were associated with a poor vital prognosis. In a multivariate analysis of prognostic factors, poor early outcome emerged as the most important parameter, closely linked to other poor outcome features such as young age and organ dysfunction. It identified a small number of patients with a poor initial response to treatment, for whom intensive treatment should be assessed in a phase II trial.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Salotti, J A, Nanduri, V, Pearce, M S, Parker, L, Lynn, R, Windebank, K P (2009). Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch. Dis. Child. 94: 376-380 [Abstract] [Full Text]  
• D'Ambrosio, N., Soohoo, S., Warshall, C., Johnson, A., Karimi, S. (2008). Craniofacial and Intracranial Manifestations of Langerhans Cell Histiocytosis: Report of Findings in 100 Patients. Am. J. Roentgenol. 191: 589-597 [Abstract] [Full Text]  
• Gadner, H., Grois, N., Potschger, U., Minkov, M., Arico, M., Braier, J., Broadbent, V., Donadieu, J., Henter, J.-I., McCarter, R., Ladisch, S., for the Histiocyte Society, (2008). Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 111: 2556-2562 [Abstract] [Full Text]  
• Prosch, H., Grois, N., Wnorowski, M., Steiner, M., Prayer, D. (2007). Long-Term MR Imaging Course of Neurodegenerative Langerhans Cell Histiocytosis. Am. J. Neuroradiol. 28: 1022-1028 [Abstract] [Full Text]  
• Hait, E., Liang, M., Degar, B., Glickman, J., Fox, V. L. (2006). Gastrointestinal Tract Involvement in Langerhans Cell Histiocytosis: Case Report and Literature Review. Pediatrics 118: e1593-e1599 [Abstract] [Full Text]  
• Prayer, D., Grois, N., Prosch, H., Gadner, H., Barkovich, A. J. (2004). MR Imaging Presentation of Intracranial Disease Associated with Langerhans Cell Histiocytosis. Am. J. Neuroradiol. 25: 880-891 [Abstract] [Full Text]  
• Donadieu, J., Rolon, M.-A., Pion, I., Thomas, C., Doz, F., Barkaoui, M., Robert, A., Deville, A., Mazingue, F., David, M., Brauner, R., Cabrol, S., Garel, C., Polak, M. (2004). Incidence of Growth Hormone Deficiency in Pediatric-Onset Langerhans Cell Histiocytosis: Efficacy and Safety of Growth Hormone Treatment. J. Clin. Endocrinol. Metab. 89: 604-609 [Abstract] [Full Text]  
• Nanduri, V. R., Lillywhite, L., Chapman, C., Parry, L., Pritchard, J., Vargha-Khadem, F. (2003). Cognitive Outcome of Long-Term Survivors of Multisystem Langerhans Cell Histiocytosis: A Single-Institution, Cross-Sectional Study. JCO 21: 2961-2967 [Abstract] [Full Text]  
• Beaumont, M., Sanz, M., Carli, P.M., Maloisel, F., Thomas, X., Detourmignies, L., Guerci, A., Gratecos, N., Rayon, C., San Miguel, J., Odriozola, J., Cahn, J.Y., Huguet, F., Vekhof, A., Stamatoulas, A., Dombret, H., Capote, F., Esteve, J., Stoppa, A.M., Fenaux, P. (2003). Therapy-Related Acute Promyelocytic Leukemia. JCO 21: 2123-2137 [Abstract] [Full Text]  
• Demirci, H., Shields, C. L., Shields, J. A., Eagle, R. C. Jr (2002). Bilateral Sequential Orbital Involvement by Eosinophilic Granuloma. Arch Ophthalmol 120: 978-979 [Full Text]  
• Jarquin-Valdivia, A. A., Buchhalter, J. (2001). Delayed Diagnosis of Pediatric Langerhans' Cell Histiocytosis: Case Report and Retrospective Review of Pediatric Cases Seen at Mayo Clinic. J Child Neurol 16: 535-538 [Abstract]  
• Stein, S. L., Paller, A. S., Haut, P. R., Mancini, A. J. (2001). Langerhans Cell Histiocytosis Presenting in the Neonatal Period: A Retrospective Case Series. Arch Pediatr Adolesc Med 155: 778-783 [Abstract] [Full Text]  
• Geissmann, F., Lepelletier, Y., Fraitag, S., Valladeau, J., Bodemer, C., Debre, M., Leborgne, M., Saeland, S., Brousse, N. (2001). Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 97: 1241-1248 [Abstract] [Full Text]  
• Siegal, G., Luntz, M., Duchmann, H., Fradis, M., Attias, D., Fridman, Z., Misselevitch, I. (2001). Quiz Case 1. Arch Otolaryngol Head Neck Surg 127: 78-80 [Full Text]  
• Tazi, A., Soler, P., Hance, A. J (2000). Rare diseases bullet 9: Adult pulmonary Langerhans' cell histiocytosis. Thorax 55: 405-416 [Full Text]  
• Kaltsas, G. A., Powles, T. B., Evanson, J., Plowman, P. N., Drinkwater, J. E., Jenkins, P. J., Monson, J. P., Besser, G. M., Grossman, A. B. (2000). Hypothalamo-Pituitary Abnormalities in Adult Patients with Langerhans Cell Histiocytosis: Clinical, Endocrinological, and Radiological Features and Response to Treatment. J. Clin. Endocrinol. Metab. 85: 1370-1376 [Abstract] [Full Text]  
• Barthez, M.-A., Araujo, E., Donadieu, J. (2000). Langerhans Cell Histiocytosis and the Central Nervous System in Childhood: Evolution and Prognostic Factors. Results of a Collaborative Study. J Child Neurol 15: 150-156 [Abstract]  
• Fernandez-Latorre, F., Menor-Serrano, F., Alonso-Charterina, S., Arenas-Jimenez, J. (2000). Langerhans' Cell Histiocytosis of the Temporal Bone in Pediatric Patients: Imaging and Follow-Up. Am. J. Roentgenol. 174: 217-221 [Abstract] [Full Text]  
• Bauer, P. W., MacDonald, C. B., Domanowski, G. F., Fuleihan, N. S. (1998). Pathologic Quiz Case 2. Arch Otolaryngol Head Neck Surg 124: 1395-1395 [Full Text]  
• Mohn, A., Acerini, C. L, Cheetham, T. D, Lightman, S. L, Dunger, D. B (1998). Hypertonic saline test for the investigation of posterior pituitary function. Arch. Dis. Child. 79: 431-434 [Abstract] [Full Text]  
• Maghnie, M., Bossi, G., Klersy, C., Cosi, G., Genovese, E., Aricò, M. (1998). Dynamic Endocrine Testing and Magnetic Resonance Imaging in the Long Term Follow-Up of Childhood Langerhans Cell Histiocytosis. J. Clin. Endocrinol. Metab. 83: 3089-3094 [Abstract] [Full Text]  
• TAZI, A., MONTCELLY, L., BERGERON, A., VALEYRE, D., BATTESTI, J.-P., HANCE, A. J. (1998). Relapsing Nodular Lesions in the Course of Adult Pulmonary Langerhans Cell Histiocytosis. Am. J. Respir. Crit. Care Med. 157: 2007-2010 [Abstract] [Full Text]  
• Howell, S J, Wilton, P, Shalet, S M (1998). Growth hormone replacement in patients with Langerhan's cell histiocytosis. Arch. Dis. Child. 78: 469-473 [Abstract] [Full Text]